Global Ulcerative Colitis Market, By Type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pan Colitis or Universal Colitis, and Fulminant Colitis), Drug Type (Anti-Inflammatory Drugs, Amino salicylates, Corticosteroids, Anti-TNF biologics, Immunosuppressant, Calcineurin Inhibitors and Other), Molecule Type (Small Molecules and Biologics), Route of Administration (Injectable and Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Store and Others) - Industry Trends and Forecast to 2030.
Ulcerative Colitis Market Analysis and Size
Ulcerative colitis is a chronic disease that directly affects the large intestine or colon. Ulcerative colitis is a disease characterized by inflammation of the large intestine resulting in abdominal pain, blood in stool, and diarrhea.
Data Bridge Market Research analyses that the global ulcerative colitis market which was USD 7,321.78 million in 2023, would rocket up to USD 10,792.98 million by 2030, and is expected to undergo a CAGR of 5.7% during the forecast period. This indicates that the market value. "Multivitamin" dominates the product type segment of the global ulcerative colitis market due to increasing awareness about ulcerative colitis. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Ulcerative Colitis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pan Colitis or Universal Colitis, and Fulminant Colitis), Drug Type (Anti-Inflammatory Drugs, Amino salicylates, Corticosteroids, Anti-TNF biologics, Immunosuppressant, Calcineurin Inhibitors and Other), Molecule Type (Small Molecules and Biologics), Route of Administration (Injectable and Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Store and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), AbbVie Inc. (U.S.), Merck & Co., Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), GlaxoSmithKline plc. (UK), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (U.S.), Abbott (U.S.), Astrazeneca (UK), Sanofi (France), Allergan (Ireland), CELGENE CORPORATION (U.S.), Bristol-Myers Squibb Company (U.S.), InDex Pharmaceuticals Holding AB (Sweden), among others.
|
|
Market Opportunities
|
|
Market Definition
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) that primarily affects the colon (large intestine) and rectum. It is characterized by inflammation and ulcers in the inner lining of the digestive tract. The exact cause of ulcerative colitis is not fully understood, but it is believed to involve a combination of genetic, environmental, and immune system factors.
Global Ulcerative Colitis Market Dynamics
Drivers
- Increasing Prevalence and Incidence
The prevalence and incidence of ulcerative colitis have been rising globally. The disease affects millions of individuals worldwide, and the numbers continue to increase, particularly in developed countries. This growing patient population drives the demand for effective treatments and healthcare services, thus fuelling the growth of the ulcerative colitis market.
- Increasing Awareness and Diagnosis
Improved awareness of ulcerative colitis among healthcare professionals and the general population has led to early detection and diagnosis of the disease. As awareness increases, more individuals with symptoms seek medical attention, leading to timely diagnosis and initiation of treatment. This trend contributes to the expansion of the ulcerative colitis market.
- Growing Healthcare Expenditure
Increased healthcare expenditure worldwide, particularly in developing economies, supports the growth of the ulcerative colitis market. With greater financial resources allocated to healthcare, there is an increased focus on providing access to quality care, including diagnosis, treatment, and management of chronic diseases like ulcerative colitis.
Opportunities
- Advancements in Medical Research
Ongoing research and developments in the understanding of ulcerative colitis have led to advancements in diagnostic tools, treatment options, and therapeutic approaches. This includes the introduction of novel medications, biological therapies, and targeted treatments that aim to provide more effective management of the disease. These advancements attract investments, drive innovation, and contribute to the growth of the market.
Restraints/Challenges
- Regulatory Challenges
Obtaining regulatory approvals for new ulcerative colitis drugs involves rigorous testing and evaluation processes. These regulatory hurdles can significantly delay the launch of new drugs, increasing development costs and limiting the market entry of innovative treatments. Adhering to these regulations and obtaining necessary approvals can be time-consuming and costly, hindering market growth.
This Ulcerative colitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Ulcerative colitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In December 2022, Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC).
Global Ulcerative Colitis Market Scope
The Ulcerative colitis market is segmented on the basis of type, drug type, molecule type, route of administration, and distribution channel. The growth amongst these segments will help you meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.
Type
- Ulcerative Proctitis
- Proctosigmoiditis
- Left-Sided Colitis
- Pan Colitis or Universal Colitis
- Fulminant Colitis
Drug Type
- Anti-Inflammatory Drugs
- Amino salicylates
- Corticosteroids
- Anti-TNF biologics
- Immunosuppressant
- Calcineurin Inhibitors
- Other
Molecule Type
- Small Molecules
- Biologics
Route of Administration
- Injectable
- Oral
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Store
- Others
Global Ulcerative Colitis Market Regional Analysis/Insights
The global ulcerative colitis market is analysed and market size insights and trends are provided by country, type, drug type, molecule type, route of administration, and distribution channel, as referenced above.
The countries covered in the global ulcerative colitis market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East & Africa.
North America is expected to dominate the global ulcerative colitis market due to the increasing prevalence of ulcerative colitis in that region. Asia-Pacific is expected to be the fastest growing region due to increasing rising awareness about ulcerative colitis.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The ulcerative colitis market also provides you with a detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for the ulcerative colitis market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the ulcerative colitis market. The data is available for the historic period 2015-2020.
Competitive Landscape and Ulcerative Colitis Market Share Analysis
The ulcerative colitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to ulcerative colitis market.
Some of the major players operating in the ulcerative colitis market are:
- Johnson & Johnson Services, Inc. (U.S.)
- Bayer AG (Germany)
- AbbVie Inc. (U.S.)
- Merck & Co., Inc. (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- GlaxoSmithKline plc. (UK)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Pfizer Inc. (U.S.)
- Abbott (U.S.)
- Astrazeneca (UK)
- Sanofi (France)
- Allergan (Ireland)
- CELGENE CORPORATION (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- InDex Pharmaceuticals Holding AB (Sweden)
SKU-